Thy-1-mediated T-cell activation requires co-expression of CD3/Ti complex

Article metrics


In addition to monoclonal antibodies against the CD3 (T3)-T-cell antigen receptor (CD3/Ti) complex1–3, several other monoclonals directed towards distinct cell surface structures on human (CD2 (T11)4 and Tp445,6) and murine (Thy-17–9, TAP10, and Ly-611) T lymphocytes are capable of activating T cells. It has been proposed that such structures may function as alternative pathways of stimulation. To examine directly whether any relationship exists between Thy-1-dependent activation phenomena and T-cell activation mediated through the CD3/Ti complex, we have transfected several CD3/Ti variants12,13 of the human T-cell line Jurkat with the murine Thy-1.2 gene. Our data indicate that in CD3/Ti, Thy-1.2+ transfectants, monoclonal antibodies against Thy-1.2 can induce a rise in cytoplasmic free calcium ([Ca2+]i), but fail to stimulate interleukin-2 (IL-2) production. The only defect in these variant cell lines responsible for the inability to produce IL-2 in response to Thy-1 stimulation was in the expression of the CD3/Ti complex, because replacement of defective Ti α- or β-chain genes reconstributed both surface expression of CD3/Ti and responsiveness to Thy-1 in the IL-2 production assay.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Chang, T. W., Kung, P. C., Gingras, S. P. & Goldstein, G. Proc. natn. Acad. Sci. U.S.A. 78, 1805–1808 (1982).

  2. 2

    Reinherz, E. L. et al. Immun. Rev. 81, 95–129 (1984).

  3. 3

    Haskins, K. et al. J. exp. Med. 157, 1149–1169 (1983).

  4. 4

    Meuer, S. C. et al. Cell 36, 897–906 (1984).

  5. 5

    Hara, T., Fu, S. M. & Hansen, J. A. J. exp. Med. 161, 1513–1524 (1985).

  6. 6

    Moretta, A., Pantako, G., Lopez-Botet, M. & Moretta, L. J. exp. Med. 162, 823–838 (1985).

  7. 7

    Gunter, K. C., Malek, T. R. & Shevach, E. M. J. exp. Med. 159, 716–730 (1984).

  8. 8

    MacDonald, H. R., Bron, C., Rousseaux, M., Horvath, C. & Cerottini, J.-C. Eur. J. Immun. 15, 495–501 (1985).

  9. 9

    Kroczek, R. A., Gunter, K. C., Seligmann, B. & Shevach, E. M. J. Immun. 136, 4379–4384 (1986).

  10. 10

    Rock, K. L. et al. J. exp. Med. 163, 315–333 (1986).

  11. 11

    Malek, T. R., Ortega, G., Chan, C., Kroczek, R. A. & Shevach, E. M. J. exp. Med. 164, 709–722 (1986).

  12. 12

    Weiss, A. & Stobo, J. D. J. exp. Med. 160, 1284–1299 (1984).

  13. 13

    Ohashi, P. S. et al. Nature 316, 606–609 (1985).

  14. 14

    Gunter, K. C., Kroczek, R. A., Shevach, E. M. & Germain, R. N. J. exp. Med. 163, 285–300 (1986).

  15. 15

    Kroczek, R. A., Gunter, K. C., Germain, R. N. & Shevach, E. M. Nature 322, 181–183 (1986).

  16. 16

    Saito, T., Weiss, A., Miller, J., Norcross, M. & Germain, R. N. Nature 325, 125–130 (1987).

  17. 17

    Weiss, A., Manger, B. & Imboden, I. J. Immun. 137, 819–825 (1986).

  18. 18

    O'Flynn, K. et al. Eur. J. Immun. 16, 580–584 (1986).

  19. 19

    June, C. H. et al. J. clin. Invest. 77, 1224–1232 (1986).

  20. 20

    Low, M. G. & Kincade, P. W. Nature 318, 62–64 (1985).

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.